|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | New insights intothe pharmacology and cytotoxicity of gemcitabine and 2',2-difluoro-deoxyuridine显示文摘 | Yeltkamp SA Pluim D van Eijndhoven MA | 2008 | Mol Cancer Ther2008，7，8： | 1 |
| 2 | Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in indi-vidual cell nuclei显示文摘 | LIEDERT B PLUIM D SCHELLENS J | 2006 | Nucleic Acids Res2006，34，6： | 1 |
| 3 | Randomizde Phase I clinical and pharmacologic study of weekly versus twice weekly dose intensive cisplatin and gemcitabine in patients with advanced non small cell lung cancer显示文摘 | Schoemaker NE Pluim D | 2003 | Clin Cancer Res2003，9，101： | 1 |
| 4 | New in- sights into the pharmacology and cytotoxicity of gemcitabine and 2', 2'-difluorodeoxyuridine 显示文摘 | Veltkamp SA Pluim D van Eijndhoven MA | 2008 | Mol Cancer Ther2008，7，8： | 1 |
| 5 | The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models显示文摘 | Breedveld P Pluim D Cipriani G | 2007 | Mol Pharmaeo2007，71，1： | 1 |
| 6 | The effect of Bcrpl (Abcg2) on the in vivo phannacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients 显示文摘 | Breedveld P Pluim D Cipriani G | 2005 | Cancer Res2005，65，： | 1 |
| 7 | The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec):implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in pati显示文摘 | Breedveld P Pluim D Cipriani G | | 0，，07： | 1 |
| 8 | Mechanism of the pharmaeokinetic interaction between methotrexate and benzimi dazoles: Potential role for breast cancer resistance protein in clinical drug-drug interactions显示文摘 | Breedveld P Zelcer N Pluim D | 2004 | Cancer Research2004，64，16： | 1 |
| 9 | Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles:potential role for- breast cancer resistance protein in clinical drug-drug interactions显示文摘 | Breedveld P Zelcer N Pluim D | 2004 | Cancer Res2004，64，16： | 1 |
| 10 | A phase I and pharmacological study with imidazolium-trans- DMSO-imidazole-tetrachlororuthenate, a novel ruthenium an- ticancer agent显示文摘 | Rademaker-Lakhai JM van den Bongard D Pluim D | 2004 | Clin Cancer Res2004，10，11： | 1 |
| 11 | In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer re sistance protein, P glycoprotein, and multidrug resistance protein 2显示文摘 | Marchetti S Oostendorp R L Pluim D van Eijndhoven M van Tellingen O Schinkel A H | 2007 | Mol Cancer Ther2007，6，： | 1 |
| 12 | Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions 显示文摘 | Breedveld P Zelcer N Pluim D | 2004 | Cancer Res2004，64，： | 1 |
| 13 | The effect of low pH on breast cancer resistance protein (ABCG2) -mediated ransport of methotrexate, 7 - hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in invitro drug transport models 显示文摘 | Breedveld P Pluim D Cipriani G | 2007 | Mol Pharmacol2007，71，1： | 1 |
| 14 | Randomizde phase I clinical and pharmacologic study of weekly versus twice weekly dose intensive cisplatin and gemcitabine in patients with advanced non small cell lung cancer显示文摘 | Schoemaker NE Pluim D | 2003 | Clin Cancer Res2003，9，10： | 1 |
| 15 | The effect of low pH on BCRP (ABCG2) -mediated transport of methotrexate,7 -hydroxymethotrexate,methotrexate diglutamate,folic acid,mitoxantrone,topotecan and resveratrol in in vitro drug transport models显示文摘 | Breedveld P Pluim D Cipriani G | 2006 | Mol Pharmacol2006，10，： | 1 |
| 16 | The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients 显示文摘 | Breedveld P Pluim D Cipriani G | 2005 | Cancer Res2005，65，： | 1 |
| 17 | The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec):implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in pati显示文摘 | Breedveld P Pluim D Cipriani G | | 0，，23： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员